Oral bioavailability and pharmacokinetics of DRF-4367, a new cox-2 inhibitor in rats-Reference-Cited by-同舟云学术

Oral bioavailability and pharmacokinetics of DRF-4367, a new cox-2 inhibitor in rats

Published:2003-06 Issue:2 Volume:28 Page:137-141
ISSN:0378-7966
Container-title:European Journal of Drug Metabolism and Pharmacokinetics
language:en
Short-container-title:Eur. J. Drug Metab. Pharmacokinet.

Author:

Ramesh Mullangi,Mamidi Rao N. V. S.,Jagannath Kota,Singh Sunil Kumar,Rao Kalleda Srinivasa,Rao Yeleswarapu Koteswar,Seshagirirao Casturi,Rajagopalan Ramanujam,Srinivas Nuggehallyr

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/BF03190502.pdf

Reference11 articles.

1. Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, Lee L Isakson P. (1994): Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA; 91: 12013–12017.

2. David L De Witt (1999): COX-2 selective inhibitors: The new super aspirins. Mol Pharmacol; 4: 625–631.

3. Amit SK, Zhiyang Zhao (2001): Discovery and design of selective cyclooxygenase-2 inhibitors as non-ulcerogenic, anti-inflammaotry drugs with potential utility as anti cancer agents. Current Drug Targets; 2: 79–106.

4. Jackson, L. M.; Hawkey, C. J. (1999): Gastrointestinal effects of COX-2 Inhibitors. Expert Opin. Invest. Drugs, 8, 963–971.

5. Scrip 2000, 2554, 20.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glucuronidation of DRF-6574, hydroxy metabolite of DRF-4367 (a novel COX-2 inhibitor) by pooled human liver, intestinal microsomes and recombinant human UDP-glucuronosyltransferases (UGT): Role of UGT1A1,1A3 and 1A8;European Journal of Drug Metabolism and Pharmacokinetics;2006-12

2. Identification of 2-hydroxymethyl-4-[5-(4-methoxyphenyl)-3-trifluoromethyl-pyrazol-1-yl]-N-propionylbenzenesulfonamide sodium as a potential COX-2 inhibitor for oral and parenteral administration;Bioorganic & Medicinal Chemistry;2006-12

3. N-Acylated sulfonamide sodium salt: A prodrug of choice for the bifunctional 2-hydroxymethyl-4-(5-phenyl-3-trifluoromethyl-pyrazol-1-yl) benzenesulfonamide class of COX-2 inhibitors;Bioorganic & Medicinal Chemistry Letters;2006-08

4. Bioavailability Enhancement of Poorly Water Soluble and Weakly Acidic New Chemical Entity with 2-Hydroxy Propyl-β-Cyclodextrin: Selection of Meglumine, a Polyhydroxy Base, as a Novel Ternary Component;Pharmaceutical Development and Technology;2006-01

5. Applicability of bioanalysis of multiple analytes in drug discovery and development: review of select case studies including assay development considerations;Biomedical Chromatography;2006